Notice: Images are for illustration only and may not reflect the exact product you receive. Brand-name medications may look different depending on their country of origin—Canadian versions, for example, often include a "PR" symbol on the packaging. Rest assured, the medication, dosage, and active ingredients will be exactly as prescribed. Canada Pharmacy Store is committed to your health and safety, and we work only with licensed pharmacies to ensure you receive trusted, high-quality medication every time.
General Medication Fact Sheet for Piqray
| Field | Information |
|---|---|
| Medication Name | Piqray |
| Generic Name | Alpelisib |
| Boxed/Label Warning | Severe hypersensitivity reactions, including anaphylaxis, and severe cutaneous adverse reactions, including Stevens-Johnson syndrome (SJS) and erythema multiforme (EM) have been reported. Discontinue Piqray immediately for any sign of severe hypersensitivity or severe cutaneous adverse reactions. |
| Purpose | Used in combination with fulvestrant to treat postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer after progression following endocrine therapy. |
| Mechanism of Action | Inhibits phosphatidylinositol-3-kinase (PI3K), specifically the PI3Kα isoform. PIK3CA mutations can lead to activation of the PI3K pathway, promoting cell growth and survival. |
| Dosage Forms | Oral tablets |
| Available Strengths | 50 mg, 150 mg |
| Dosage Frequency | Once daily, taken with fulvestrant. |
| Common Side Effects | Hyperglycemia, diarrhea, nausea, decreased appetite, rash, fatigue, vomiting, stomatitis, weight loss, hypocalcemia |
| Serious Side Effects | Severe allergic reactions, severe skin reactions, hyperglycemia, diarrhea, pneumonitis, liver problems |
| Drug Interactions | Strong CYP3A4 inhibitors and inducers may alter alpelisib concentrations. Avoid concomitant use if possible. |
| Important Notes | Monitor blood glucose levels regularly due to the risk of hyperglycemia. Patients should be pre-treated with antiemetics and antidiarrheals. |
| Storage | Store at room temperature away from moisture and light. |
| Missed Dose | If a dose is missed, it should not be taken later that day. The next dose should be taken at the usual time the next day. |
| Alternatives | Everolimus, Palbociclib, Ribociclib, Letrozole, Anastrozole |
Piqray Alternatives
| Medication | Mechanism of Action | Notes |
|---|---|---|
| Everolimus (Afinitor) | mTOR inhibitor | Used in HR-positive, HER2-negative breast cancer; often combined with exemestane. |
| Palbociclib (Ibrance) | CDK4/6 inhibitor | Used in HR-positive, HER2-negative breast cancer; often combined with aromatase inhibitors or fulvestrant. |
| Ribociclib (Kisqali) | CDK4/6 inhibitor | Used in HR-positive, HER2-negative breast cancer; often combined with aromatase inhibitors or fulvestrant. |
| Letrozole (Femara) | Aromatase inhibitor | First-line endocrine therapy for postmenopausal women with HR-positive breast cancer. |
| Anastrozole (Arimidex) | Aromatase inhibitor | Alternative first-line endocrine therapy for postmenopausal women with HR-positive breast cancer. |
Piqray Side Effects
| Common Side Effects | Serious Side Effects |
|---|---|
| Hyperglycemia | Severe allergic reactions (anaphylaxis) |
| Diarrhea | Severe skin reactions (Stevens-Johnson syndrome, erythema multiforme) |
| Nausea | Pneumonitis |
| Decreased appetite | Liver problems (hepatotoxicity) |
| Rash | Hyperglycemia leading to diabetic ketoacidosis or hyperosmolar hyperglycemic state |
Piqray Dosage Guide
| Condition | Starting Dose | Maintenance Dose | Administration Notes |
|---|---|---|---|
| HR-positive, HER2-negative, PIK3CA-mutated Advanced Breast Cancer | 300 mg once daily | 300 mg once daily | Taken with fulvestrant 500 mg intramuscularly on days 1, 15, and 29, then monthly. Take Piqray immediately after food. |
Piqray Price With And Without Insurance
| Purchase Context | Estimated Price |
|---|---|
| With Insurance | $100 |
| Without Insurance (U.S.) | $22,000 |
| From CPS | $9,340 |
